Streetbeat News

Price Targets

ZG

JMP Securities analyst Nicholas Jones has upgraded Zillow Group (ZG) from Market Perform to Market Outperform and set a price target of $60.

Portfolio Pulse from Benzinga Newsdesk

December 12, 2023 | 10:43 am

SRE

JP Morgan analyst Christopher Turnure has upgraded Sempra (NYSE:SRE) from Neutral to Overweight and increased the price target from $78 to $86.

Portfolio Pulse from Benzinga Newsdesk

December 12, 2023 | 10:41 am

HPQ

Morgan Stanley analyst Erik Woodring has upgraded HP (NYSE:HPQ) from Equal-Weight to Overweight and increased the price target from $31 to $35.

Portfolio Pulse from Benzinga Newsdesk

December 12, 2023 | 10:36 am

SONO

Morgan Stanley analyst Erik Woodring upgraded Sonos (NASDAQ:SONO) from Equal-Weight to Overweight and increased the price target from $17 to $20.

Portfolio Pulse from Benzinga Newsdesk

December 12, 2023 | 10:35 am

GS

RL

Goldman Sachs analyst Brooke Roach upgraded Ralph Lauren (NYSE:RL) from Sell to Neutral and set a price target of $132.

Portfolio Pulse from Benzinga Newsdesk

December 12, 2023 | 10:32 am

PVH

Goldman Sachs analyst Brooke Roach has upgraded PVH Corp (NYSE:PVH) from Neutral to Buy and set a price target of $126.

Portfolio Pulse from Benzinga Newsdesk

December 12, 2023 | 10:30 am

M

Citigroup analyst Paul Lejuez has downgraded Macy's (NYSE:M) from Neutral to Sell and set a new price target of $14.

Portfolio Pulse from Benzinga Newsdesk

December 12, 2023 | 10:28 am

DTC

B. Riley Securities analyst Anna Glaessgen has initiated coverage on Solo Brands (NYSE:DTC) with a Neutral rating and set a price target of $5.5 for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

December 12, 2023 | 10:21 am

CPB

Wells Fargo analyst Chris Carey has initiated coverage on Campbell Soup (NYSE:CPB) with an Equal-Weight rating and set a price target of $47 for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

December 12, 2023 | 10:18 am

KRTX

Deutsche Bank analyst Neena Bitritto-Garg has initiated coverage on Karuna Therapeutics (NASDAQ:KRTX) with a Buy rating and set a price target of $227 for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

December 12, 2023 | 10:13 am